US Trustee Flags Sacklers' Release, Atty Fees In Purdue Plan

Law360 (July 19, 2021, 10:28 PM EDT) -- The U.S. Trustee's Office on Monday objected to Purdue Pharma's proposed Chapter 11 plan, pointing to the "extraordinarily broad release" of the Sackler family from opioid crisis-related claims and up to $500 million in attorney fees "without court oversight and approval."

In a filing lodged with a New York federal bankruptcy court, U.S. Trustee William Harrington urged the court not to confirm the proposed plan as is. Allowing the Sacklers to escape liability for their alleged role in directing the marketing and sale of painkiller OxyContin, which is claimed to have contributed to the opioid crisis in the U.S., constitutes "an...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!